Global Blood Therapeutics found using ticker (GBT) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 68.5 and 60 calculating the average target price we see 64.5. With the stocks previous close at 68.49 this is indicating there is a potential downside of -5.8%. The day 50 moving average is 63.7 and the 200 day moving average is 38.56. The company has a market capitalisation of $4,621m. Visit the company website at: https://www.gbt.com
The potential market cap would be $4,352m based on the market concensus.
Global Blood Therapeutics, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics was incorporated in 2011 and is headquartered in South San Francisco, California.
